Search results
Results from the WOW.Com Content Network
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Voluntarily withdrawn from US market because of risk of Progressive multifocal leukoencephalopathy (PML). Returned to market July 2006. Nefazodone: 2004 Europe, Australia, New Zealand and Canada [35] [36] [37] Branded version withdrawn by originator in several countries in 2007 for hepatotoxicity. Generic versions available. Still available in ...
The drug is sometimes described as a typical antipsychotic, [5] and sometimes described as an atypical antipsychotic. [6] Chemically, molindone is an indole and is structurally distinct from many other antipsychotics. [2] Molindone was first described by 1966 [7] and was introduced for medical use in 1974. [8] It remains marketed only in the ...
Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. [3] [4] It is taken by mouth. [3] Side effects of pimavanserin include peripheral edema and confusion. [3]
This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in December 2017.
For all antipsychotics, the British National Formulary recommends a gradual dose reduction when discontinuing to avoid acute withdrawal syndrome or rapid relapse. [22] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. [23] Other symptoms may include restlessness, increased sweating, and trouble sleeping. [23]
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), [1] [2] are a group of antipsychotic drugs (antipsychotic drugs in general are also known as tranquilizers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) largely introduced after the 1970s and used to treat psychiatric ...
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. [19] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. [20] Other symptoms may include restlessness, increased sweating, and trouble sleeping. [20]